Latigo Biotherapeutics (NASDAQ:LTGO) Posts Quarterly Earnings Results

Latigo Biotherapeutics (NASDAQ:LTGO) released its quarterly earnings data on Thursday. The company reported ($27.59) earnings per share for the quarter, Zacks reports.

Latigo Biotherapeutics Price Performance

NASDAQ LTGO traded up $0.71 during mid-day trading on Thursday, reaching $22.48. 229,298 shares of the stock were exchanged, compared to its average volume of 226,738. Latigo Biotherapeutics has a 1 year low of $17.22 and a 1 year high of $25.93.

Insiders Place Their Bets

In other Latigo Biotherapeutics news, major shareholder Foresite Capital Management V, bought 140,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the transaction, the insider directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director James B. Tananbaum purchased 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. This trade represents a 7.49% increase in their position. The disclosure for this purchase is available in the SEC filing.

Key Headlines Impacting Latigo Biotherapeutics

Here are the key news stories impacting Latigo Biotherapeutics this week:

• Positive Sentiment: Latigo completed an upsized initial public offering, including the underwriters’ full overallotment exercise, raising $397.4 million in gross proceeds. Combined with existing cash, the company expects to fund operations into 2029, supporting continued development of its pipeline without an immediate need for additional capital. Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Results from Latigo’s onzotrigine, formerly known as LTG-001, abdominoplasty trial were published in The New England Journal of Medicine. The positive data in moderate-to-severe acute pain provide third-party validation for the company’s non-opioid pain-treatment program and could improve its partnering and commercial prospects. Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: New coverage from Leerink Partners, Jefferies, Guggenheim and Goldman Sachs was bullish, with outperform or buy ratings and price targets ranging from $36 to $73. The coverage may be supporting investor interest and expanding institutional visibility.
• Neutral Sentiment: Latigo appointed Naomi Lowy, M.D., a former FDA anesthesia and pain-medicine official, as senior vice president of global regulatory affairs, potentially strengthening the company’s regulatory strategy as its programs advance.
• Negative Sentiment: Latigo reported a quarterly loss of $27.59 per share. The substantial loss highlights the company’s ongoing dependence on cash reserves and future clinical or commercial progress, despite the recently strengthened balance sheet.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LTGO shares. Leerink Partners initiated coverage on shares of Latigo Biotherapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 target price for the company. Guggenheim assumed coverage on Latigo Biotherapeutics in a research note on Tuesday. They set a “buy” rating and a $50.00 price objective for the company. Jefferies Financial Group began coverage on Latigo Biotherapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 price objective for the company. Wall Street Zen upgraded Latigo Biotherapeutics to a “hold” rating in a research note on Saturday, August 15th. Finally, The Goldman Sachs Group assumed coverage on Latigo Biotherapeutics in a report on Tuesday. They set a “buy” rating and a $73.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $52.25.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.